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A positive effect of intra-articular platelet-rich plasma (PRP) injection has been discussed for osteoarthritic joint conditions in the
last years. The purpose of this study was to evaluate PRP injection into the trapeziometacarpal (TMC) joint. We report about ten
patients with TMC joint osteoarthritis (OA) that were treatedwith 2 intra-articular PRP injections 4weeks apart. PRPwas produced
using the Double Syringe System (Arthrex Inc., Naples, Florida, USA). A total volume of 1.47 ± 0.25mL PRP was injected at the
first injection and 1.5 ± 0.41mL at the second injection, depending on the volume capacity of the joint. Patients were evaluated
using VAS, strength measures, and the Mayo Wrist score and DASH score after 3 and 6 months. VAS significantly decreased from
6.2±1.6 to 5.4±2.2 at six-month follow-up (𝑃 < 0.05).TheDASH score was unaffected; however, theMayoWrist score significantly
improved from 46.5 ± 18.6 to 67.5 ± 19.0 at six-month follow-up (𝑃 = 0.05). Grip was unaffected, whereas pinch declined from
6.02±2.99 to 3.96±1.77 at six-month follow-up (𝑃 < 0.05).We did not observe adverse events after the injection of PRP, except one
occurrence of a palmar wrist ganglion, which resolved without treatment. PRP injection for symptomatic TMCOA is a reasonable
therapeutic option in early stages TMC OA and can be performed with little to no morbidity.
1. Introduction
Several conservative and operative techniques have been
described for the treatment of trapeziometacarpal (TMC)
joint osteoarthritis (OA) over the last 70 years. In general,
OA involves a perturbed joint environment at the cellular
level with alterations in the composition of the synovial
fluid. As a consequence, chondrocytes become “activated”
with increased proliferation, production of matrix-degrading
enzymes, cytokines, and cytokine receptors [1]. Finally, the
inadequate healing response to synovial inflammation results
in further structural cartilage degradation [2].
Besides splint and exercise regimes, hyaluronate injec-
tions have been evaluated as conservative treatment in
placebo-controlled randomized trials for symptomatic treat-
ment of basal thumb arthritis [3, 4]. All performed operative
procedures, like trapeziectomy, trapeziectomy with ligament
reconstruction, arthrodesis, or implant arthroplasty, demon-
strated good clinical results [5, 6].
Platelet-rich plasma (PRP) is an autologous blood prod-
uct that contains an increased concentration of platelets and
emerged as a safe treatment modality to accelerate healing of
musculoskeletal injuries [7]. Platelets containmore than 5000
proteins, of whichmore than 300 are released upon activation
[8]. Particularly, among these bioactive proteins are growth
factors and cytokines.
PRP injection into joints can modify the biological
microenvironment inside the joint.Thereby, PRP affects local
and infiltrating cells, mainly synovial cells, endothelial cells,
immune cells, and cellular components of cartilage and bone
[9]. Ultimately, it is believed to reduce the inflammatory
process and alter the joint homeostasis of anabolism and
catabolism in cartilage [10]. Numerous PRP formulations are
used in experimental and clinical research and yield products
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Figure 1: (a) Anteroposterior and lateral X-rays of the right TMC joint of a 71-year-old female with OA of the TMC and scaphotrapezio-
trapezoid (STT) joints classified as Eaton and Littler III.The patient reported pain since 71 weeks and had undergone anti-inflammatory pain
medication as needed since then. (b) Fluoroscopic images of the right hand before and after PRP injection resulting in TMC and STT joint
distension due to intra-articular PRP application.
with different cellular compositions and biological charac-
teristics [11]. Leukocyte-reduced PRP has proven superior
over leukocyte-rich PRP in the treatment of OA in vitro.
It has been shown that the interaction of white blood cells
with chondrocytes and synoviocytes results in a significantly
higher the release of proinflammatory cytokines IL-1b and IL-
6 [12, 13]. For this reason, we recently characterized and opti-
mized a leukocyte-reduced PRP for the intra-articular appli-
cation [14]. We disabled the brake after the centrifugation
process and achieved a further significant reduction of white
blood cell content in PRP in comparison to PRP produced
according to the manufacturer’ instructions.
Three randomized hyaluronan-controlled trials [15–17]
and one placebo-controlled clinical trial for OA of the knee
joint [18] demonstrated decreased pain and improved func-
tion after PRP injections in patients with symptomatic knee
OA.The implications for PRP treatment of OA in other joints
are unknown. To our knowledge, there is no study in the
literature investigating multiple PRP injections for the treat-
ment of TMC joint OA.
The primary aim of this study was to gather first results
on the clinical effects of PRP injections for the treatment of
different stages of TMC OA. It was hypothesized that intra-
articular treatment with leukocyte-reduced PRP would lead
to improvements in pain and function of the TMC joint
during the 6-month follow-up.
2. Methods
The study was approved by the local ethics committee of
the University of Regensburg (15-104-0274). A total of ten
patients with TMC OA were treated with 2 intra-articular
PRP injections 4weeks apart at theUniversityMedical Center
Regensburg (Figures 1(a) and 1(b)). Two patients had received
a steroid or hyaluronan injection in the years before PRP
treatment, both with short-term pain relief. The condition
was diagnosed using standard radiographic and clinical
criteria: basal joint tenderness, thumb or wrist pain at rest
or with activity, joint stiffness, decreased mobility, deformity,
instability, and decreased hand function. No splinting was
used after each injection. Rest was recommended for 1-2 days
with full range of motion as tolerated. During the course of
treatment, all patients did not take corticosteroids or nons-
teroidal anti-inflammatory drugs (NSAIDs).
2.1. Radiologic Classification. All X-rays have been evaluated
and classified by a blinded radiologist with the Eaton and
Littler Classification as follows [19]:
I: normal joint appearance or less than one-third
subluxation.
II: decrease of joint space, osteophytes less than 2mm,
and one-third subluxation or more.
III: advanced joint distraction, subchondral cysts and
sclerosis, and osteophytes greater than 2mm.
IV: involvement of several joint surfaces.
2.2. PRP Samples. Venous blood (15mL) was drawn directly
into the Arthrex Double Syringe (Arthrex Inc., Naples,
Florida, USA) for the production of autologous conditioned
plasma (ACP) using a winged infusion set (Sarstedt AG &
Co., Nu¨mbrecht, Germany). The ACP double syringe was
processed using a Hettich Rotofix 32a centrifuge at 1500 rpm
for 4 minutes with brake disabled as characterized previously
[14]. The whole blood was separated into two distinct layers
by centrifugation, whereas a plasma layer appeared on the top
and the red/white blood cell layer was apparent on the bot-
tom. The plasma containing the platelets (PRP) was isolated
by drawing the inner syringe according to the manufac-
turer’ instructions. Our previous work revealed a concen-
tration of platelets by approximately 2.4 times in PRP
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(567.6 ± 143.1 × 103/𝜇L; 95% confidence interval: 514.2–621.1
× 103/𝜇L) in comparison to venous blood (232.5 ± 45.7 ×
103/𝜇L; 95% confidence interval: 215.5–249.6 × 103/𝜇L),
whereas a significant reduction of white blood cells to a
marginal concentration in PRP was observed [14].
Thereafter, PRP was injected under sterile conditions into
the TMC joint under fluoroscopic guidance from the dorsal
side by the senior author. No local anesthetic was used.
All patients received an injection of 1-2mL into the joint
depending on the volume capacity of the joint. The injection
was repeated after four weeks.
2.3. Outcome Measures and Follow-Up. Prior to the first
injection, baseline outcome measures and descriptive statis-
tics were collected prospectively for all patients. Descriptive
statistics included age, gender, and hand dominance. Patients
completed the validated DASH questionnaire and a visual
analog scale (VAS) for pain with activity. Moreover, the
Mayo Wrist score was included. The grip strength and pinch
strength were measured 3 times and the mean value was
calculated. All patients were scheduled for follow-up visits
with identical evaluation at 3 and 6 months after the first
injection.
Statistical analysis was performed using SPSS software
package (version 20, IBM SPSS, Chicago, Illinois), whereas
all graphswere prepared by usingGraphPad Prism (version 5,
Statcon, La Jolla, California). All data were tested for normal
distribution applying the Shapiro-Wilk test. Paired 𝑡-test and
One-Way Analysis of Variance (ANOVA) with Bonferroni
correction were used to analyze all normally distributed
parameters (DASH score, Mayo Wrist score, and pinch and
grip power) depending on the time of examination (first
examination and 3 months and 6 months after treatment).
The Wilcoxon Signed-Rank test with Bonferroni correction
was applied to analyze differences between the VAS out-
comes. Differences between groups, based on the Eaton
and Littler Classification, were investigated by the One-Way
Analysis of Variance (ANOVA) and Wilcoxon Signed-Rank
test with Bonferroni correction. The Spearman Correlation
test was used to analyze correlations between all parameters.
Descriptive data are expressed in terms of mean ± standard
deviation. The level of significance was set at 𝑃 = 0.05 for all
statistical tests.
3. Results
Ten patients were identified for this study. The mean age
of the included patients was 56.1 ± 9.9 years at the time
of the first injection. All patients were followed up for 6
months. The study cohort comprised 8 women and 2 men
with involvement of the dominant hand in 3 patients and the
nondominant hand in 7 patients (Table 1). A total volume of
1.47 ± 0.25mL PRP was injected into the TMC joint at the
first injection and 1.5 ± 0.41mL at the second injection.
3.1. Clinical Outcome. At the time of the first injection,
patients reported pain with a VAS of 6.2 ± 1.6, which
significantly decreased to 4.0 ± 2.4 at three-month follow-up
and 5.4 ± 2.2 at six-month follow-up (both 𝑃 < 0.05). VAS
Table 1: Baseline patient characteristics.
Age 56.1 ± 9.9 (49.3–62.7)
Female/male 8/2
Dominant hand 3
Eaton score II/III/IV 2/3/5
VAS 6.2 ± 1.6 (5.1–7.3)
DASH score 32.9 ± 11.9 (24.4–41.5)
Mayo Wrist score 46.5 ± 18.6 (33.2–59.8)
Pinch 6.0 ± 3.0 (3.9–8.2)
Grip 16.4 ± 9.9 (9.3–23.5)
Data expressed asmean± standard deviation (95% confidence interval). VAS
= visual analog scale.
increased significantly by 1.4 points from three- to six-month
follow-up (𝑃 < 0.05).TheDASH score remained similar with
32.9±11.9 at baseline and 20.4±14.7 at three-month and 26.8±
18.9 at 6-month follow-up (𝑃 ≥ 0.24). The Mayo Wrist score
significantly improved from 46.5±18.6 to 68.3±18.5 at three-
month follow-up (𝑃 = 0.05) and to 67.5 ± 19.0 at six-month
follow-up (𝑃 = 0.05) (Table 2). Overall, 2 patients were very
satisfied with the result of the treatment, 5 were satisfied, 3
patients indicated neither satisfied nor unsatisfied, and no
patient was dissatisfied.
3.2. Trapeziometacarpal Osteoarthritis-Depending Results. To
analyze the influence of severity of TMC OA according to
the Eaton and Littler Classification, we created 4 subgroups
of patients classified as Eaton and Littler I to IV. Two patients
were classified as Eaton II, three patients as Eaton III, and five
patients as Eaton IV.We found a positive correlation between
patients’ age and severity of TMC OA according to the Eaton
and Littler Classification (𝑟 = 0.6, 𝑃 < 0.01).
Patients with moderate OA graded as Eaton and Littler
II reported pain with a VAS of 4.5 ± 0.7, which significantly
decreased to 0.5±0.7 at three-month and 2.0±1.4 at six-month
follow-up (both 𝑃 < 0.05) (Figure 2). Moreover, the DASH
score and Mayo Wrist score significantly improved, both at
three- and six-month follow-up (all 𝑃 ≤ 0.05) with 36.7 ±
15.3 to 0.0 ± 0.0 and 27.5 ± 17.7 to 92.5 ± 10.6, respectively
(Figures 3 and 4).The strength measures pinch and grip were
not affected by the PRP treatment at three and six months (all
𝑃 = 1.0) (Figures 5 and 6).
In patients with a more severe OA graded as Eaton and
Littler III and IV, the reported outcome measures VAS, the
DASH score, andMayoWrist score did not change as a result
of the PRP treatment (all 𝑃 ≥ 0.06) (Figures 2–4). Similarly,
the strength measures did not improve (all 𝑃 = 1.0). Looking
at patients graded as Eaton IV, the pinch even decreased over
timewith 5.8±1.4 kg at baseline, 3.8±1.5 kg after threemonths
(𝑃 = 0.089), and 2.9 ± 0.8 kg after six months (𝑃 = 0.01)
(Figure 5).
4. Discussion
Several conservative treatment options have been evaluated
in the treatment of TMC OA in the past [3]. PRP as
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Table 2: Clinical outcome.
First examination 3 months 𝑃 value 6 months 𝑃 value
VAS 6.2 ± 1.6 (5.1–7.3) 4.0 ± 2.4 (2.3–5.7) <0.05 5.4 ± 2.2 (3.8–7.0) <0.05
DASH score 32.9 ± 11.9 (24.4–41.5) 20.4 ± 14.7 (10.0–30.1) 0.24 26.8 ± 18.9 (13.3–40.3) 1
Mayo Wrist score 46.5 ± 18.6 (33.2–59.8) 68.3 ± 18.5 (54.1–82.6) 0.05 67.5 ± 19.0 (53.9–81.1) 0.05
Pinch 6.0 ± 3.0 (3.9–8.2) 4.6 ± 2.1 (3.1–6.1) 0.12 4.9 ± 1.8 (2.7–5.2) <0.05
Grip 16.4 ± 9.9 (9.3–23.5) 16.8 ± 10.2 (9.5–24.1) 0.83 16.7 ± 10.4 (9.2–24.1) 0.91
Data expressed as mean ± standard deviation (95% confidence interval). VAS: visual analog scale.
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Figure 2:The course of visual analog scale (VAS) for pain depending
on the severity of TMC OA. Data expressed as mean ± standard
deviation. ∗𝑃 ≤ 0.05.
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Figure 3: The course of the DASH score depending on the severity
of TMC OA. Data expressed as mean ± standard deviation. ∗𝑃 ≤
0.05.
an autologous blood-derived product can modify the bio-
logical microenvironment inside the joint by reducing the
inflammatory process and recreate joint homeostasis within
the inflamed joint [9]. Several clinical trials demonstrated
decreased pain and improved function after PRP injections
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Figure 4: The course of the Mayo Wrist score depending on the
severity of TMC OA. Data expressed as mean ± standard deviation.
∗ represents 𝑃 < 0.05.
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Figure 5:The course of the pinch depending on the severity of TMC
OA. Data expressed as mean ± standard deviation. ∗ represents 𝑃 <
0.05.
in patients with symptomatic OA of the knee joint [15–18].
Very little is known about the implications for PRP treatment
of OA in other joints.Therefore, the primary aim of this study
was to gather first results about the clinical effects of PRP
injections for the treatment of different stages of TMC OA.
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Figure 6: The course of the grip depending on the severity of TMC
OA. Data expressed as mean ± standard deviation.
These first results indicate that intra-articular injections
of PRP for TMC OA represent a safe conservative treat-
ment modality. Patients with mild to moderate TMC OA
experience persistent decreased pain at six-month follow-up
after two intra-articular injections of PRP. Furthermore, these
patients revealed a clinically significant improvement of the
DASH score and Mayo Wrist score. Patients with a more
severe OA graded as Eaton and Littler III and IV did not
experience a persistent benefit.
In the current study, we did not observe adverse events
after the injection of PRP, except one occurrence of a
palmar wrist ganglion, which resolved without treatment.
The injected PRP volume was depending on the size of the
joint. PRP was injected until there was no possibility to add
more into the joint. The applied intra-articular volume of
about 1.5mL was similar at both injections for every patient,
however, less than in other studies investigating viscosupple-
mentation [3, 20]. The resulting joint distension was super-
vised fluoroscopically and resolved after onemonth when the
second injectionwas performed. Progressive instability of the
TMC joint due to weakening of the articular capsule and lig-
aments can be observed after corticosteroid injections at rare
intervals [20]. We did not observe progressive instability of
the TMC joint in any of our patients. Considering the patho-
genesis of primary TMCOA, further weakening of the capsu-
lar and ligament stabilizers should be prevented for successful
treatment [21].
The most important finding of the present study was that
patients demonstrated a significant pain relief after two PRP
injections at 3- and 6-month follow-up. Patients with mild to
moderate TMC OA, especially, experienced a persistent pain
relief.
Patients classified as Eaton II had been free of pain after
6 months, and patients classified as Eaton III and IV had
pain relief after 3 months, which did not fully retain up to
6 months. Similar studies about corticosteroid injection also
report limited success for patients with late stages of TMCOA
[22, 23].
We are aware of two prospective, randomized clinical
trials that investigate the efficacy of viscosupplementation
for TMC OA [3, 20]. Stahl et al. demonstrated significant
improvement of strength tests after hyaluronan injection in
comparison to corticosteroid injection at six-month follow-
up. Similarly, Heyworth et al. demonstrated significant
improvement of strength tests and pain when compared to
baseline in the hyaluronan group only. In the current study,
the strength measures did not improve. Looking at patients
graded as Eaton IV, the pinch even decreased over time.
A few prospective studies on the effectiveness of PRP on
knee degeneration revealed significant improvements in pain
and clinical outcome [24]. Moreover, patients with early OA
of the knee joint demonstrated significantly better clinical
results with multiple PRP injections. Accordingly, patients
with mild TMCOA experienced significant improvements of
Mayo Wrist score and pain at 6-month follow-up. The better
clinical results observed in patients with early OA could be
explained by a better responsiveness to growth factors in less
degenerated joints with more vital cells. Therefore, it was
hypothesized that multiple PRP injections would yield an
effective treatment option for early OA [15]. However, further
studies with higher patient numbers will have to reproduce
our first results and will have to elucidate on the number and
frequency of PRP injections for effective treatment.
The presented study has a number of limitations: first of
all, the study design lacks a control or placebo group. Second,
the results of this clinical trial are based on the limited
number of ten patients and therefore have to be interpreted
with caution.Third, the subgroup analysis according on to the
Eaton and Littler Classification based on radiographic fea-
tures does not necessarily reflect the symptoms of pain expe-
rienced by the patient. However, the strengths of the present
study are that all data were collected prospectively and com-
prise a detailed inquiry about clinical and functional outcome
after intra-articular PRP injections for TMC OA.
5. Conclusion
At present, PRP injection into symptomatic OA of the TMC
joint is a reasonable therapeutic option in early stages of
TMC OA and can be performed with little to no morbidity.
This study represents preliminary data to support PRP as
another option in the conservative management of TMC OA
to restore joint homeostasis in the inflamed joint. Further
research should be conducted to confirm our findings and
should address the value of autologous PRP injection versus
viscosupplementation or steroid injection.
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